DWC20151

DWC20151 is a small molecule investigational drug developed by Daewoong Pharmaceutical. It has been evaluated in at least one completed Phase 1 clinical trial designed to assess its pharmacokinetics and safety profile in healthy male subjects. The study was a randomized, open-label, oral dose, crossover design comparing DWC20151 with another compound (DWC20152). As of the latest available information, no specific therapeutic indication or mechanism of action has been publicly disclosed for DWC20151. Its development status remains early-stage with no reported approvals or advanced clinical trials beyond Phase 1[1][2][3][5].